These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 34555481

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials.
    Sticherling M, Nikkels AF, Hamza AM, Kwong P, Szepietowski JC, El Sayed M, Ghislain PD, Khotko AA, Patekar M, Ortmann CE, Forrer P, Papanastasiou P, Keefe D.
    Am J Clin Dermatol; 2023 Sep; 24(5):821-835. PubMed ID: 37341961
    [Abstract] [Full Text] [Related]

  • 5. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.
    Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, Papanastasiou P, Keefe D, Patekar M, Charef P, Zhang L, Cafoncelli S, Papavassilis C.
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):938-947. PubMed ID: 33068444
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.
    Warren RB, Blauvelt A, Poulin Y, Beeck S, Kelly M, Wu T, Geng Z, Paul C.
    Br J Dermatol; 2021 Jan; 184(1):50-59. PubMed ID: 32594522
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB.
    Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
    [Abstract] [Full Text] [Related]

  • 8. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
    Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, You R, Bruin G, Djimopoulos J, Paguet B, Charef P, Patekar M, Keefe D.
    Br J Dermatol; 2022 Jun; 186(6):942-954. PubMed ID: 34981829
    [Abstract] [Full Text] [Related]

  • 9. Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis.
    Blair HA.
    Paediatr Drugs; 2021 Nov; 23(6):601-608. PubMed ID: 34665445
    [Abstract] [Full Text] [Related]

  • 10. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M.
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [Abstract] [Full Text] [Related]

  • 11. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C.
    Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
    [Abstract] [Full Text] [Related]

  • 12. Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study.
    Okubo Y, Ohtsuki M, Morita A, Yamaguchi M, Shima T, Tani Y, Nakagawa H, Extension Study Japanese Subgroup.
    J Dermatol; 2019 Mar; 46(3):186-192. PubMed ID: 30672623
    [Abstract] [Full Text] [Related]

  • 13. Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.
    Lee MG, Huang YH, Lee JH, Lee SC, Kim TG, Aw DC, Bao W, Dee CMA, Guana A, Tsai TF.
    J Dermatol; 2019 Sep; 46(9):752-758. PubMed ID: 31342560
    [Abstract] [Full Text] [Related]

  • 14. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, Ziv M, Pinter A, Vender R, Hugot S, You R, Milutinovic M, Thaçi D.
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [Abstract] [Full Text] [Related]

  • 15. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, Blauvelt A.
    Lancet; 2019 Sep 07; 394(10201):831-839. PubMed ID: 31402114
    [Abstract] [Full Text] [Related]

  • 16. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis.
    Cai L, Zhang JZ, Yao X, Gu J, Liu QZ, Zheng M, Zhang SF, Xu JH, Li CX, Cheng H, Guo Q, Pan WL, Li SQ, Li RY, Guo ZP, Song ZQ, Li SS, Dong XQ, Wang L, Fu R, Regnault P, Charef P, Mazur R, Patekar M.
    Chin Med J (Engl); 2020 Nov 20; 133(22):2665-2673. PubMed ID: 33060370
    [Abstract] [Full Text] [Related]

  • 17. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
    Langley RG, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren RB, Paul C, Szepietowski JC, Tsai TF, Hampele I, You R, Charef P, Papavassilis C.
    Br J Dermatol; 2023 Feb 10; 188(2):198-207. PubMed ID: 36763857
    [Abstract] [Full Text] [Related]

  • 18. Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE).
    Warren RB, Barker JNWB, Finlay AY, Burden AD, Kirby B, Armendariz Y, Williams R, Hatchard C, Khare S, Griffiths CEM.
    Br J Dermatol; 2020 Jul 10; 183(1):60-70. PubMed ID: 31628677
    [Abstract] [Full Text] [Related]

  • 19. Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single-center, uncontrolled, prospective study in 36 weeks.
    Chen XB, Zheng YX, Ye LR, Chen XY, Man XY.
    Dermatol Ther; 2022 Dec 10; 35(12):e15911. PubMed ID: 36209377
    [Abstract] [Full Text] [Related]

  • 20. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
    Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, Shima T, Papavassilis C, Nakagawa H, ERASURE Study Japanese subgroup.
    J Dermatol; 2014 Dec 10; 41(12):1039-46. PubMed ID: 25354738
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.